OUTLOOK THERAPEUTICS, INC. (OTLK) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -55.64M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.11M USD | Cost of Goods and Services Sold |
| Research and development | 17.36M USD | Research and Development Expense |
| Selling, general and administration | 36.00M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-55.64M | (m) | $1.11M | $17.36M | $36.00M | (m) |
| 2026-03-31 | $-60.57M | (m) | $1.54M | $21.25M | $38.12M | (m) |
| 2025-12-31 | $-58.94M | (m) | (m) | $21.15M | $36.60M | (m) |
| 2025-09-30 | $-67.06M | $1.41M | $1.36M | $27.18M | $39.94M | -4744.25% |
| 2025-06-30 | $-72.62M | (m) | (m) | $33.72M | (m) | (m) |
| 2025-03-31 | $-76.44M | (m) | (m) | $37.79M | (m) | (m) |
| 2024-12-31 | $-82.99M | (m) | (m) | $46.89M | (m) | (m) |
| 2024-09-30 | $-71.70M | (m) | (m) | $41.76M | (m) | (m) |
| 2024-06-30 | $-61.28M | (m) | (m) | $34.18M | (m) | (m) |
| 2024-03-31 | $-59.86M | (m) | (m) | $34.08M | (m) | (m) |
| 2023-12-31 | $-47.76M | (m) | (m) | $21.12M | (m) | (m) |
| 2023-09-30 | $-53.13M | (m) | (m) | $26.45M | (m) | (m) |
| 2023-06-30 | $-54.65M | (m) | (m) | $30.50M | (m) | (m) |
| 2023-03-31 | $-53.54M | (m) | (m) | $30.65M | (m) | (m) |
| 2022-12-31 | $-65.61M | (m) | (m) | $42.32M | (m) | (m) |
| 2022-09-30 | $-63.07M | (m) | (m) | $42.33M | (m) | (m) |
| 2022-06-30 | $-62.52M | (m) | (m) | $43.28M | (m) | (m) |
| 2022-03-31 | $-56.97M | (m) | (m) | $40.57M | (m) | (m) |
| 2021-12-31 | $-50.69M | (m) | (m) | $36.88M | (m) | (m) |
| 2021-09-30 | $-51.73M | (m) | (m) | $38.96M | (m) | (m) |
| 2021-06-30 | $-48.30M | (m) | (m) | $36.65M | (m) | (m) |
| 2021-03-31 | $-48.71M | (m) | (m) | $36.59M | (m) | (m) |
| 2020-12-31 | $-42.85M | (m) | (m) | $32.44M | (m) | (m) |
| 2020-09-30 | $-36.84M | (m) | (m) | $26.34M | (m) | (m) |
| 2020-06-30 | $-39.52M | (m) | (m) | $26.17M | (m) | (m) |
| 2020-03-31 | $-33.28M | (m) | (m) | $22.03M | (m) | (m) |
| 2019-12-31 | $-34.23M | (m) | (m) | $23.58M | (m) | (m) |
| 2019-09-30 | $-36.30M | $8.15M | (m) | $23.81M | (m) | -445.60% |
| 2019-06-30 | $-36.02M | $3.06M | (m) | $26.46M | (m) | -1175.43% |
| 2019-03-31 | $-37.60M | $3.25M | (m) | $27.86M | (m) | -1155.92% |
| 2018-12-31 | $-36.72M | $3.38M | (m) | $26.52M | (m) | -1085.40% |
| 2018-09-30 | $-29.64M | $3.09M | (m) | $18.50M | (m) | -960.12% |
| 2018-06-30 | $-20.14M | $5.22M | (m) | $13.66M | (m) | -386.01% |
| 2018-03-31 | $-20.26M | $4.75M | (m) | $12.02M | (m) | -426.57% |
| 2017-12-31 | $-21.26M | $4.28M | (m) | $10.98M | (m) | -496.81% |
| 2017-09-30 | $-35.88M | $3.81M | (m) | $23.81M | (m) | -941.36% |
| 2017-06-30 | $-43.64M | $1.40M | (m) | $25.96M | (m) | -3107.68% |
| 2017-03-31 | $-58.23M | $1.60M | (m) | $33.74M | (m) | -3648.33% |
| 2016-12-31 | $-53.24M | $2.29M | (m) | $33.68M | (m) | -2327.24% |
| 2016-09-30 | $-51.76M | $2.98M | (m) | $33.10M | (m) | -1737.10% |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-46.56M | $5.22M | (m) | $38.88M | (m) | -892.13% |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |